Handelsbanken Fonder AB Grows Stake in Charles River Laboratories International, Inc. $CRL

Handelsbanken Fonder AB raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 26.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,606 shares of the medical research company’s stock after purchasing an additional 3,069 shares during the period. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $2,285,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the 2nd quarter worth $29,000. Rothschild Investment LLC raised its stake in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in Charles River Laboratories International in the third quarter valued at about $31,000. Geneos Wealth Management Inc. boosted its holdings in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares in the last quarter. Finally, Allworth Financial LP grew its stake in shares of Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CRL. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Evercore boosted their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Citigroup raised their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Stock Performance

CRL opened at $175.71 on Wednesday. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $228.88. The firm has a 50 day moving average of $196.77 and a two-hundred day moving average of $180.59. The firm has a market capitalization of $8.65 billion, a PE ratio of -59.36, a P/E/G ratio of 3.05 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The business had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.